CU24558B1 - Anticuerpos monoclonales que reconocen al receptor del factor de crecimiento epidérmico y sus fragmentos derivados - Google Patents
Anticuerpos monoclonales que reconocen al receptor del factor de crecimiento epidérmico y sus fragmentos derivadosInfo
- Publication number
- CU24558B1 CU24558B1 CU2017000148A CU20170148A CU24558B1 CU 24558 B1 CU24558 B1 CU 24558B1 CU 2017000148 A CU2017000148 A CU 2017000148A CU 20170148 A CU20170148 A CU 20170148A CU 24558 B1 CU24558 B1 CU 24558B1
- Authority
- CU
- Cuba
- Prior art keywords
- egfr
- fragments
- growth factor
- factor receptor
- epidermal growth
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7023—(Hyper)proliferation
- G01N2800/7028—Cancer
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
<p>Esta invención proporciona nuevos anticuerpos (Ac) y fragmentos que reconocen Ia región extracelular del receptor del factor de crecimiento epidérmico (EGFR) humano con una mayor afinidad que el Ac nimotuzumab, por lo que pueden reconocer con mayor eficiencia, líneas con mediana expresión del EGFR. La presente invención se relaciona además, con las composiciones farmacéuticas que comprenden como principal activo los Acs y fragmentos divulgados y su uso en Ia terapia de tumores con expresión del EGFR. Además, los Acs y fragmentos divulgados son útiles cuando están enlazados a un radioisótopo o fluoróforo en Ia localización de tumores que presenten el EGFR. Adicionalmente, se pueden utilizar en direccionalizar Ia respuesta inmune a las células tumorales EGFR positivas cuando se fusionan a proteínas o dominios proteicos de interés inmunológico.<br /> </p>
Priority Applications (17)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU2017000148A CU24558B1 (es) | 2017-11-28 | 2017-11-28 | Anticuerpos monoclonales que reconocen al receptor del factor de crecimiento epidérmico y sus fragmentos derivados |
| SG11202004746VA SG11202004746VA (en) | 2017-11-28 | 2018-11-20 | Antibodies of increased affinity for the epidermal growth factor receptor and its derived fragments |
| NZ765527A NZ765527B2 (en) | 2018-11-20 | Antibodies with increased affinity for the epidermal growth factor receptor and fragments derived therefrom | |
| EA202091328A EA202091328A1 (ru) | 2017-11-28 | 2018-11-20 | Антитела с повышенной аффинностью к рецептору эпидермального фактора роста и происходящие из них фрагменты |
| KR1020207018489A KR102708617B1 (ko) | 2017-11-28 | 2018-11-20 | 표피성장인자 수용체에 대한 증가된 친화도를 가지는 항체 및 이의 단편 |
| EP18830130.3A EP3719037A1 (en) | 2017-11-28 | 2018-11-20 | Antibodies with increased affinity for the epidermal growth factor receptor and fragments derived therefrom |
| PCT/CU2018/050004 WO2019105492A1 (es) | 2017-11-28 | 2018-11-20 | Anticuerpos de afinidad incrementada por el receptor del factor de crecimiento epidérmico y sus fragmentos derivados |
| US16/767,356 US11718676B2 (en) | 2017-11-28 | 2018-11-20 | Antibodies with increased affinity for the epidermal growth factor receptor and fragments derived therefrom |
| MX2020005490A MX2020005490A (es) | 2017-11-28 | 2018-11-20 | Anticuerpos de afinidad incrementada por el receptor del factor de crecimiento epidermico y sus fragmentos derivados. |
| CN201880077704.5A CN111417654B (zh) | 2017-11-28 | 2018-11-20 | 具有增加的对于表皮生长因子受体的亲和力的抗体及其衍生片段 |
| BR112020010075-7A BR112020010075A2 (pt) | 2017-11-28 | 2018-11-20 | anticorpos de afinidade aumentada para o receptor de fator de crescimento epidérmico e seus fragmentos derivados |
| CA3082759A CA3082759A1 (en) | 2017-11-28 | 2018-11-20 | Antibodies with increased affinity for the epidermal growth factor receptor and fragments derived therefrom |
| AU2018377764A AU2018377764B2 (en) | 2017-11-28 | 2018-11-20 | Antibodies with increased affinity for the epidermal growth factor receptor and fragments derived therefrom |
| JP2020547282A JP7396992B2 (ja) | 2017-11-28 | 2018-11-20 | 上皮成長因子受容体に対する親和性が増加した抗体およびそれに由来するフラグメント |
| TW107142095A TWI820058B (zh) | 2017-11-28 | 2018-11-26 | 對表皮生長因子受體具有增加的親和性之抗體及其衍生之片段 |
| ARP180103458A AR113843A1 (es) | 2017-11-28 | 2018-11-27 | Anticuerpos de afinidad incrementada por el receptor del factor de crecimiento epidérmico y sus fragmentos derivados |
| ZA2020/03866A ZA202003866B (en) | 2017-11-28 | 2020-06-25 | Antibodies with increased affinity for the epidermal growth factor receptor and fragments derived therefrom |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU2017000148A CU24558B1 (es) | 2017-11-28 | 2017-11-28 | Anticuerpos monoclonales que reconocen al receptor del factor de crecimiento epidérmico y sus fragmentos derivados |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CU20170148A7 CU20170148A7 (es) | 2019-07-04 |
| CU24558B1 true CU24558B1 (es) | 2021-12-08 |
Family
ID=64959051
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU2017000148A CU24558B1 (es) | 2017-11-28 | 2017-11-28 | Anticuerpos monoclonales que reconocen al receptor del factor de crecimiento epidérmico y sus fragmentos derivados |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US11718676B2 (es) |
| EP (1) | EP3719037A1 (es) |
| JP (1) | JP7396992B2 (es) |
| KR (1) | KR102708617B1 (es) |
| CN (1) | CN111417654B (es) |
| AR (1) | AR113843A1 (es) |
| AU (1) | AU2018377764B2 (es) |
| BR (1) | BR112020010075A2 (es) |
| CA (1) | CA3082759A1 (es) |
| CU (1) | CU24558B1 (es) |
| EA (1) | EA202091328A1 (es) |
| MX (1) | MX2020005490A (es) |
| SG (1) | SG11202004746VA (es) |
| TW (1) | TWI820058B (es) |
| WO (1) | WO2019105492A1 (es) |
| ZA (1) | ZA202003866B (es) |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU22545A1 (es) * | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
| ME01222B (me) | 2005-02-28 | 2013-06-20 | Eisai R&D Man Co Ltd | Nova kombinovana upotreba jedinjenja sulfonamida u liječenju kancera |
| EP2190878A1 (en) * | 2007-09-06 | 2010-06-02 | Genmab A/S | Novel methods and antibodies for treating cancer |
| KR20130096731A (ko) * | 2010-09-08 | 2013-08-30 | 할로자임, 아이엔씨 | 조건부 활성 치료적 단백질을 평가，확인 또는 진화시키는 방법 |
| US8691231B2 (en) * | 2011-06-03 | 2014-04-08 | Merrimack Pharmaceuticals, Inc. | Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies |
| EP2822970A1 (en) | 2012-03-08 | 2015-01-14 | Halozyme, Inc. | Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof |
| DK2906248T3 (en) | 2012-10-12 | 2019-03-04 | Medimmune Ltd | Pyrrolobenzodiazepines and their conjugates |
| JP2017514471A (ja) | 2014-04-23 | 2017-06-08 | ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム | キメラ抗原受容体（ｃａｒ）並びにその製造及び使用方法 |
| CN104530237B (zh) * | 2014-12-31 | 2017-09-05 | 百泰生物药业有限公司 | 抗Her1的治疗性抗体 |
| EP3310440A1 (de) | 2015-06-22 | 2018-04-25 | Bayer Pharma Aktiengesellschaft | Binder-wirkstoff-konjugate (adcs) und binder-prodrug-konjugate (apdcs) mit enzymatisch spaltbaren gruppen |
| SG10201912553QA (en) * | 2015-07-27 | 2020-02-27 | Innocimab Pte Ltd | Treatment of patients diagnosed with pancreatic ductal adenocarcinoma using monoclonal antibodies against the epidermal growth factor receptor (egfr) |
-
2017
- 2017-11-28 CU CU2017000148A patent/CU24558B1/es unknown
-
2018
- 2018-11-20 KR KR1020207018489A patent/KR102708617B1/ko active IP Right Grant
- 2018-11-20 MX MX2020005490A patent/MX2020005490A/es unknown
- 2018-11-20 AU AU2018377764A patent/AU2018377764B2/en active Active
- 2018-11-20 EA EA202091328A patent/EA202091328A1/ru unknown
- 2018-11-20 EP EP18830130.3A patent/EP3719037A1/en active Pending
- 2018-11-20 SG SG11202004746VA patent/SG11202004746VA/en unknown
- 2018-11-20 JP JP2020547282A patent/JP7396992B2/ja active Active
- 2018-11-20 BR BR112020010075-7A patent/BR112020010075A2/pt unknown
- 2018-11-20 CN CN201880077704.5A patent/CN111417654B/zh active Active
- 2018-11-20 CA CA3082759A patent/CA3082759A1/en active Pending
- 2018-11-20 US US16/767,356 patent/US11718676B2/en active Active
- 2018-11-20 WO PCT/CU2018/050004 patent/WO2019105492A1/es active Application Filing
- 2018-11-26 TW TW107142095A patent/TWI820058B/zh active
- 2018-11-27 AR ARP180103458A patent/AR113843A1/es unknown
-
2020
- 2020-06-25 ZA ZA2020/03866A patent/ZA202003866B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021504484A (ja) | 2021-02-15 |
| WO2019105492A1 (es) | 2019-06-06 |
| TW201932485A (zh) | 2019-08-16 |
| KR20200090236A (ko) | 2020-07-28 |
| BR112020010075A2 (pt) | 2020-10-13 |
| TWI820058B (zh) | 2023-11-01 |
| NZ765527A (en) | 2024-02-23 |
| EA202091328A1 (ru) | 2020-09-17 |
| AU2018377764A1 (en) | 2020-07-09 |
| CU20170148A7 (es) | 2019-07-04 |
| CN111417654A (zh) | 2020-07-14 |
| US20210002375A1 (en) | 2021-01-07 |
| CA3082759A1 (en) | 2019-06-06 |
| SG11202004746VA (en) | 2020-06-29 |
| KR102708617B1 (ko) | 2024-09-25 |
| AR113843A1 (es) | 2020-06-17 |
| JP7396992B2 (ja) | 2023-12-12 |
| US11718676B2 (en) | 2023-08-08 |
| ZA202003866B (en) | 2022-06-29 |
| CN111417654B (zh) | 2023-11-10 |
| AU2018377764B2 (en) | 2022-09-29 |
| EP3719037A1 (en) | 2020-10-07 |
| MX2020005490A (es) | 2020-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20200152A1 (es) | Receptores de union a antigeno mejorados | |
| CY1122060T1 (el) | Συνδυαστικη θεραπευτικη χρηση αντισωματων και ενδογλυκοσιδασεων | |
| EA202091710A1 (ru) | Антитела против cd73 и способы их применения | |
| CY1124106T1 (el) | Συνθεσεις μεταφορεα-αντισωματος και μεθοδοι παρασκευης και χρησης αυτων | |
| MX2020009774A (es) | Anticuerpos contra proteína alfa reguladora de señal y métodos de uso. | |
| BR112019002687A2 (pt) | receptores de antígeno quimérico que direcionam bcma e métodos de uso dos mesmos | |
| BR112019011450A2 (pt) | células naturais killer modificadas e uso das mesmas | |
| CL2017001296A1 (es) | Anticuerpos contra cd73 y sus usos | |
| AR115389A1 (es) | Anticuerpo antagonista de cd73 | |
| AR093557A1 (es) | Anticuerpos anti-ceacam5 y usos de estos | |
| CY1122456T1 (el) | Μονοκλωνικα αντισωματα εναντιον παραγοντα 15 αυξησης και διαφοροποιησης (gdf-15), και χρησεις αυτων για θεραπευτικη αγωγη καρκινικης καχεξιας και καρκινου | |
| NZ604003A (en) | Monoclonal antibodies against her2 | |
| EA201991005A1 (ru) | Антитела и полипептиды, направленные против cd127 | |
| EA202092202A1 (ru) | Конструкции антител к ror | |
| UY34995A (es) | Formulaciones de anticuerpo y proteína | |
| GT201100223A (es) | Proteínas de unión específicas y sus usos | |
| CL2019000366A1 (es) | Nuevos receptores de linfocitos t e inmunoterapia basada en el uso de los mismos. | |
| BR112013004914A2 (pt) | "composições de pele e métodos de uso das mesmas". | |
| AR103726A1 (es) | Cristales de anticuerpos monoclonales anti-pd-1 humanos | |
| BR112022000371A2 (pt) | Anticorpos claudin18 e métodos de tratamento contra câncer | |
| CR10971A (es) | Vacuna | |
| UA118354C2 (uk) | Антитіло до рецептора колонієстимулювального фактора (кфс-1r) | |
| MX2020002921A (es) | Anticuerpos para claudin6 y métodos para tratar el cáncer. | |
| MX2020005555A (es) | Construcciones inmunogenicas de peptidos de tau. | |
| PL422231A1 (pl) | Komórki immunologiczne CAR do leczenia nowotworów |